Search results
Showing 1751 to 1800 of 2004 results for news
New treatment for advanced breast cancer recommended by NICE
Around 300 people are set to benefit following NICE’s recommendation of talazoparib for treating a type of locally advanced or metastatic breast cancer in final draft guidance published today (19 January 2024).
New one-a-day tablet for people with severe hair loss due to alopecia areata recommended by NICE
NICE and NHS England announce plan to enable innovative tech to be adopted quicker
NHS patients in England will benefit from faster access to the most innovative and cutting-edge medical technologies under new plans.
NICE's Early Value Assessment for Medtech: panning for nuggets of innovation gold
Early Value Assessment for Medtech and how it will offer a rapid assessment of digital products, devices and diagnostics for clinical effectiveness and value for money.
NICE Chairman, Sharmila Nebhrajani, today announced Dr Samantha Roberts as incoming Chief Executive.
NICE has launched a free learning course that provides an introduction to health technology assessment (HTA).
Angela sets out to understand some of the challenges, benefits and considerations of setting up and running a virtual ward, from the perspective of teams on the front lines.
Working in partnership to harness the potential of digital technology
Nicola Bent talks about NICE and the AHSN Network’s important ambition to address market access challenges for digital innovation as part of the collaboration agreement.
A new treatment that increases the chance of a successful kidney transplant has been recommended by NICE in final draft guidance.
As we launch an early version of the online service, mapping out the regulatory and health technology assessment pathway, Ciara Cook invites future users to help shape this exciting new initiative.
A refreshed Evidence Standards Framework for Digital Health Technologies
Two exciting developments which will accelerate NICE’s efforts to deliver innovation to the health and care system faster.
NICE says new triple negative advanced breast cancer drug too expensive for NHS use
NICE has issued draft guidance which does not recommend sacituzumab govitecan for treating locally advanced or metastatic triple negative breast cancer.
NICE is making changes to simplify our offer to the life sciences industry.
NICE approves life-changing gene therapy for treating spinal muscular atrophy
A new one-off gene therapy for babies with the rare genetic disorder spinal muscular atrophy (SMA) is set to become the most expensive treatment ever approved by NICE.
How is NICE supporting digital health technology developers?
Richard Chivers, operations manager for NICE Scientific Advice, looks at how we’re supporting digital health technology developers and helping them with some of the challenges around evidence requirements and adoption within the NHS.
Self-harm is everyone's business, NICE says in new draft guideline
All professionals working across the health and social care system have a role to play in supporting people who self-harm and the issue should not just be seen as the responsibility of those with mental health expertise, NICE has said in a new draft guideline.
Using our guidance and resources in continuing professional development (CPD)
Registered social workers must demonstrate the use of evidence and research to inform their practice in order to meet professional standards. This is echoed in Social Work England’s continuing professional development (CPD) standards.
Increasing the capacity of our technology appraisals - the proportionate way
Jenniffer Prescott describes how we are trialling a proportionate approach to technology appraisals, which we expect will increase our capacity by 20% from 2023/24.
NICE calls for further research into the treatment of chronic lipoedema
NICE has today issued interventional procedures guidance on the use of liposuction for the treatment of chronic lipoedema.
Working at the forefront of neurodegenerative disease research
Claire Hawksworth reveals NICE’s role in a global partnership to better understand neurodegenerative conditions and speed up delivery of innovative treatments.
Dr Sam Roberts, chief executive of NICE, celebrates the NHS on its 75th anniversary. She discusses how NICE has supported the NHS with its recent achievements. She also highlights how NICE is evolving; through driving value-based healthcare to support the NHS as it adapts to meet current challenges.
Over 500 people a year can access a new life extending lung cancer treatment
An innovative life-extending drug for treating mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults is being recommended by NICE as an option for use within the Cancer Drugs Fund.
NHS Talking Therapies for anxiety and depression services saw record referrals in 2023/24.
Benefits of new Alzheimer's treatment lecanemab are too small to justify the cost to the NHS
Our draft recommendation follows analysis of clinical trial evidence and reviewing the benefits of slowing disease progression, with the cost of treatment.
More than 700 people set to benefit from new treatment option for advanced lymphoma.
NICE recommends innovative technology for people with breast cancer
A magnetic marker liquid injected into people with invasive breast cancer will help surgeons discover if the cancer has spread.
Children with a rare, fatal, genetic disorder will be able to benefit from a new one-off treatment under new NICE guidance.
Healthier lifestyle can help to ease osteoarthritis symptoms says NICE
Exercise has an important role to play in helping people living with osteoarthritis NICE says in draft updated guidelines published today (29th April 2022).
Following the successful evaluation of Zio XT, developers of digital health technologies are encouraged to engage with NICE through one of several different routes.
New guidance aims to achieve fairer outcomes for looked-after children and young people
Looked after children and young people should be considered ‘one of their own’ by carers, to help them to reach their full potential, new NICE draft guidelines say.
New LSE master's degree in Evaluation of Health Care Interventions and Outcomes
NICE is collaborating with the London School of Economics and Political Science (LSE) to develop an executive master’s degree in health care decision-making.
NICE has recommended a new option for people with difficult-to-treat multiple myeloma
Around 5,700 cases of multiple myeloma are diagnosed each year in the UK. NICE has recommended a new option for people with difficult-to-treat multiple myeloma.
This indicator covers the percentage of patients aged between 25 and 84 years with a new diagnosis of hypertension or type 2 diabetes, recorded in the preceding 12 months (excluding those with pre-existing cardiovascular disease, chronic kidney disease, familial hypercholesterolaemia or type 1 diabetes) who have had a consultation for full formal cardiovascular disease risk assessment between 3 months before or 3 months after date of diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM132
NICE’s methods and processes for evaluating new treatments for use in the NHS are appropriate for the new class of Alzheimer’s drugs but key issues need to be considered, a new report has found.
Home News Podcasts Learn more about NICE's updated menopause guideline Podcasts 29 November 2024 Listen About this episode Our guests are
Around 105,000 people with type 1 diabetes could benefit from NICE’s draft recommendation
Around 1,500 people aged 12 years and over with melanoma are set to benefit from pembrolizumab, a drug that reduces the chance of it returning.
NICE approves routine use of drug combination for advanced breast cancer
A life-extending drug combination for some people with advanced breast cancer will now be available for routine use in the NHS.
NICE welcomes Dr Michael Borowitz as new NICE non-executive director
New NICE non-executive director appointment approved by the Secretary of State for Health and Social Care
NICE conditionally recommends 5 promising technologies for Parkinson's disease
These promising technologies could help improve symptoms and quality of life for people with Parkinson’s disease.
Routine funding recommended for Duchenne muscular dystrophy gene therapy ataluren
NICE has today published final guidance which recommends ataluren (also called Translarna and made by PTC Therapeutics) for treating Duchenne muscular dystrophy (DMD) caused by a nonsense mutation.
Further treatment option for triple-negative breast cancer recommended
NICE has today (8 November 2022) published final draft guidance which recommends pembrolizumab as an option for people with a type of breast cancer called triple-negative breast cancer.
NICE recommends treatment for people with short bowel syndrome
A potentially life-changing treatment has been recommended for people with short bowel syndrome who are aged 1 year and above.
New guidance recommends transplant with good bacteria taken from poo
Up to 500 people each year could be treated using faecal microbiota transplant for multiple recurrences of Clostridium difficile infections.
NICE recommends novel treatment for debilitating inherited skin condition
Around 670 people in England with skin wounds caused by a rare inherited disorder to benefit from a new treatment to help the healing process.
Artificial intelligence to speed up contouring in radiotherapy treatment planning
Nine artificial intelligence technologies can be used to help plan the treatment of those undergoing external beam radiotherapy for cancers
NICE launches first modular update to its methods and processes
NICE’s methods and processes now include a proportionate approach to technology appraisals, and a new way of updating recommendations on COVID-19 treatments.
NICE recommended treatment for Parkinson's set to benefit hundreds
Around 900 adults with advanced Parkinson’s are set to benefit from new treatment foslevodopa–foscarbidopa after NICE approved it for NHS use in final draft guidance published today (26 October 2023).
Hundreds of people with some forms of urothelial cancer to receive new treatment
People with locally advanced or metastatic urothelial cancer are set to benefit from a new treatment – avelumab – following its recommendation for funding
Hundreds of thousands set to benefit from new treatment to prevent heart attacks and strokes
NICE has published final draft guidance which recommends icosapent ethyl for reducing the risk of heart attacks and strokes in adults who have raised blood fats.